Short Interest in Talphera, Inc. (NASDAQ:TLPH) Decreases By 33.4%

Talphera, Inc. (NASDAQ:TLPH) was the recipient of a significant decrease in short interest in March. As of March 31st, there was short interest totalling 69,300 shares, a decrease of 33.4% from the March 15th total of 104,100 shares. Currently, 0.4% of the shares of the company are short sold. Based on an average daily volume of 64,700 shares, the days-to-cover ratio is currently 1.1 days.

Talphera Trading Up 4.3 %

Shares of NASDAQ TLPH opened at $0.48 on Friday. Talphera has a 12-month low of $0.45 and a 12-month high of $1.27. The firm has a market capitalization of $8.22 million, a price-to-earnings ratio of -0.70 and a beta of 0.19. The firm has a 50 day moving average of $0.56 and a 200 day moving average of $0.67.

Talphera (NASDAQ:TLPH) last posted its quarterly earnings data on Monday, March 31st. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.14. Sell-side analysts predict that Talphera will post -0.64 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. HC Wainwright reiterated a “buy” rating and issued a $6.00 price objective on shares of Talphera in a report on Tuesday, April 1st. Rodman & Renshaw began coverage on shares of Talphera in a report on Tuesday, January 28th. They set a “buy” rating and a $4.00 price objective for the company. Finally, RODMAN&RENSHAW raised shares of Talphera to a “strong-buy” rating in a research report on Tuesday, January 28th.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.